Bioequivalence Study of Pramipexole Dihydrochloride Extended-release Tablets in Healthy Chinese Subjects

Comparative Pharmacokinetics for Bioequivalence of Pramipexole Dihydrochloride Extended-Release Tablets in Fasting and Fed Chinese Healthy Volunteers: A Randomized, Open-label, Single-dose, Crossover Study

The study compared pramipexole dihydrochloride extended-release tablets (Test formulation) by Haisco Pharmaceutical Group Co., Ltd. with the reference formulation (MIRAPEX ER®，Boehringer Ingelheim GmbH of Germany) to evaluate the bioequivalence of single dose in Chinese healthy subjects under fasting and fed conditions.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Drug: Test formulation（pramipexole dihydrochloride extended-release tablets）; Drug: Reference formulation（MIRAPEX ER®）

• Study Type: Interventional
• Enrollment (Actual): 49
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Sichuan
    • Chengdu, Sichuan, China
      • The General Hospital of Western Theater Command PLA

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Healthy male and female subjects aged 18 years or older (inclusive);
2. Body weight ≥ 50 kg for males and ≥ 45 kg for females, with body mass index (BMI) between 19 and 26 (inclusive);
3. No clinically significant abnormalities in vital signs, physical examination, laboratory tests, 12-lead electrocardiogram (ECG), chest X-ray (posteroanterior view), or abdominal ultrasound at screening；
4. All subjects must be willing to use appropriate contraceptive measures from the screening period, throughout the trial drug administration period, and until one month after drug discontinuation;
5. Subjects must understand and comply with the study procedures, voluntarily participate, and sign the informed consent form.

Exclusion Criteria:

1. Subjects with serious systemic diseases, infectious diseases, or mental disorders that, in the investigator's opinion, make them unsuitable for participation in this study;
2. History of clinically significant ECG abnormalities or family history of long QT syndrome (grandparents, parents, and siblings);
3. Known or suspected history of allergy to the investigational drug or drugs with a similar chemical structure;

4. Presence of conditions that may affect drug absorption, distribution, metabolism, or excretion, including but not limited to any of the following:

   • History of inflammatory bowel disease, gastritis, gastrointestinal ulcer, gastrointestinal bleeding, or other clinically significant gastrointestinal abnormalities.
   • History of major gastrointestinal surgery (e.g., gastrectomy, gastrointestinal anastomosis, enterectomy, gastric bypass, gastric partitioning, or gastric banding).
   • History of clinically significant renal disease or impaired renal function, or laboratory abnormalities at screening.
   • Liver disease or laboratory abnormalities indicative of clinically significant hepatic impairment at screening.
5. Subjects with positive test results for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or syphilis antibody;
6. History of drug abuse or alcohol abuse within 12 months prior to screening (consuming more than 2 units of alcohol per day or more than 14 units per week; 1 unit = 355 mL beer, 30 mL liquor, or 150 mL wine);
7. Average daily smoking of more than 5 cigarettes within 3 months prior to screening (assessed by interview at screening), or inability to refrain from smoking during the entire study period;
8. Blood donation or blood loss of ≥ 400 mL within 3 months prior to screening;
9. Participation in another clinical trial within 3 months prior to screening;
10. Use of any prescription medication within 4 weeks prior to screening;
11. Use of over-the-counter drugs, health supplements, herbal medicines, or traditional Chinese medicines within 2 weeks prior to screening. Refusal to discontinue any beverages or foods containing xanthines, such as caffeine (coffee, tea, cola, chocolate, etc.), from 48 hours before dosing until the end of the study;
12. Pregnant or breastfeeding women;
13. History of orthostatic hypotension, sudden vertigo, or transient syncope;
14. Subjects deemed unsuitable for participation in the study by the investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Test formulation; pramipexole dihydrochloride extended-release tablets (0.375 mg/table)，Manufacturer: Haisco Pharmaceutical Group Co., Ltd	Drug: Test formulation（pramipexole dihydrochloride extended-release tablets）; Test formulation (pramipexole dihydrochloride extended-release tablets, Haisco Pharmaceutical Group Co., Ltd), A single oral dose of 0.375 mg, taken with 240mL of water
Experimental: Reference formulation; pramipexole dihydrochloride extended-release tablets (MIRAPEX ER®，0.375 mg/table) Manufacturer: Boehringer Ingelheim GmbH of Germany	Drug: Reference formulation（MIRAPEX ER®）; Reference formulation (pramipexole dihydrochloride extended-release tablets, Boehringer Ingelheim GmbH of Germany), A single oral dose of 0.375 mg, taken with 240mL of water

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cmax (Maximum Concentration)	The pharmacokinetic parameters of pramipexole in plasma	From the start of administration to 72 hours post-dose
AUC(0-t) (Area Under the Concentration-Time Curve from time 0 to time t)	The pharmacokinetic parameters of pramipexole in plasma	From the start of administration to 72 hours post-dose
AUC(0-∞) (Area Under the Concentration-Time Curve from time 0 to infinity)	The pharmacokinetic parameters of pramipexole in plasma	From the start of administration to 72 hours post-dose

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
AEs (Adverse Events)	The incidence and severity of AEs	From the time of signing ICF (Informed Consent Form) to the end of follow-up，up to 10 days

Collaborators and Investigators

• Sponsor: Haisco Pharmaceutical Group Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): March 16, 2017
• Primary Completion (Actual): April 11, 2017
• Study Completion (Actual): February 12, 2018

Study Registration Dates

• First Submitted: April 2, 2026
• First Submitted That Met QC Criteria: April 2, 2026
• First Posted (Actual): April 9, 2026

Study Record Updates

• Last Update Posted (Actual): April 14, 2026
• Last Update Submitted That Met QC Criteria: April 9, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Other Study ID Numbers: HSK-80-BE-2016

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No